VIFOR PHARMA INVESTOR PRESENTATION

Page created by Nicole Jacobs
 
CONTINUE READING
VIFOR PHARMA INVESTOR PRESENTATION
AUGUST 2021

              VIFOR PHARMA

              INVESTOR PRESENTATION
LEADING PORTFOLIO IN TARGET THERAPY AREAS

                                              Iron
                                                                                                                      Nephrology                                                               Cardio-renal
                                              deficiency

Commercial
 products
                                                                                                                                                                     2

                                                                                                                              3                                4

                                                                                                              Rayaldee®5                         Avacopan6
   Pipeline                                          VIT-27631                                                                KorsuvaTM 7
   products                                                                                                    Vadadustat8                        ANG-37779

1) Restriction of iron availability, i.e. for treating non-transfusion-dependent thalassemia or sickle cell disease 2) Licensed from F. Hoffmann-La Roche AG 3) Licensed from Pfizer Inc.
4) Joint commercialisation agreement with Janssen Pharmaceuticals Inc. 5) Licensed from OPKO Health, Inc. 6) Licensed from ChemoCentryx, Inc. 7) Licensed from Cara Therapeutics, Inc.
8) Licensed from Akebia Therapeutics, Inc., subject to certain conditions and limited to selling vadadustat to certain providers within the US dialysis market 9) Licensed from Angion Biomedica Corp.

AUGUST 2021                                                                                                                                                                                                   2
VIFOR PHARMA STRATEGIC FOCUS
THREE AREAS AS BASIS FOR FUTURE GROWTH

                                        ▪ Global market leader
              1       Iron Deficiency   ▪ High unmet medical need
                                        ▪ Ferinject®: defined by manufacturing process

                  2      Nephrology

              3
                      Cardio-Renal

AUGUST 2021                                                                              3
IRON DEFICIENCY – MARKET OVERVIEW
I.V. IRON SEGMENT OF THE IRON MARKET
IN-MARKET SALES                                                                                                                                                 2’072   2’060
In CHF million
                                                                                                                                                        1’801
                                                                                                                                                                 578     587
                                                                                                                                                1’524    490
                                                                                                                         1’352
                                                                                                  1’166                                          433             455     459
                                                                           1’003                                           418                           423
       848                    831                    880                                            386
                                                                                                                                                 391
                                                                             358
        285                                           332                                                                  393
                               303
                                                                                                    382
                                                                                                                                                                1’039   1’014
                                                                             387                                                                         889
        475                    400                    379                                                                                        699
                                                                                                                           542
                                                                                                    399
                                                      170                    258
         88                    129
       2012                   2013                   2014                   2015                   2016                   2017                  2018    2019    2020    2021

       Ferinject®              Venofer®               Other i.v. irons

Source: quarterly IQVIATM MIDAS® panel, GERS, Insight Health, DLI, moving annual total Q1-2021. Average 2020 exchange rates have been applied

AUGUST 2021                                                                                                                                                                     4
FERINJECT®/INJECTAFER®
GROWTH BACK AT PRE-PANDEMIC LEVELS
NET SALES EVOLUTION
CHF million                                           +13.3%         ▪ Q1 2021 in line with prior year despite
180                                                            173     lock-down measures still in place in
                                +22.3%
                                                                       many countries
160                              148            153
                                          147
140                                                                  ▪ Strong recovery in Q2 2021, driven by
                  120                                                  easing of restrictions in key countries
120                                                    114

100                                                                  ▪ Q1 and Q2 2021 growth back to pre
 80                                                                    COVID-19 level, with 22.3% and
                                                                       13.3% compared to Q1 and Q2 2019,
 60
                                                                       respectively
 40
 20

                                 Q1                    Q2

      2019          2020           2021
CER = constant exchange rates

AUGUST 2021                                                                                                  5
IRON DEFICIENCY – FERINJECT® INDICATIONS
INDICATIONS SPLIT DRIVEN BY REGIONAL FOCUS

CAGR
’16-201                              40%                          40%

                                                                                                      35%

                                                                                                                                                              26%
Sales
                              21%                                       20%
share by                                                    19%
indication                                                                                15%                           14%
                                                                                                                                                        12%
                                                                                                                                     9%                                9%             9%
                                                                                                                                                                             6%
                                           3%                                                                                                                                              2%

                              Heart failure                Patient blood                    Gastro-                     Nephrology                      Oncology /   Women’s health    Others
                                                           management                      enterology                                                   Hematology
                                                                                                           EU4 and the UK                        US

1) Pre-COVID-19 year-over-year growth rate as per end of Q1 2020
Source: quarterly IQVIATM MIDAS® panel, GERS, Insight Health, moving annual total Q1-2021 in 100mg equivalents; EU4: Germany, France, Italy and Spain

AUGUST 2021                                                                                                                                                                                     6
1

    IRON DEFICIENCY – FERINJECT® PBM1 EUROPE
    MAJOR GROWTH OPPORTUNITY
    PATIENT DROP-OFF – EU4 AND THE UK
                                            135K
                                                                           221K
                                                                                                370K
                                                                                                                                                  ▪ PBM strongly supported by
                                                                                                                                                    World Health Organization

                                                                                                                                                  ▪ Estimated savings per patient
                                                                                                                                                    of CHF 850 vs usual care2
             1’933K
                                                                                                                                                  ▪ Additional real world
                                                                                                                    1’207K                          evidence data expected in
                                                                                                                                                    2021

    With iron deficiency              Other i.v. iron                   Ferinject®         Transfusion             Not treated

    Source: Vifor Pharma analysis, 2019, EU4: Germany, France, Italy and Spain       1) Patient Blood Management       2) Froessler B, et al. Risk Manag Health Policy 2018;11:77–82;

    AUGUST 2021                                                                                                                                                                         7
VIFOR PHARMA STRATEGIC FOCUS
THREE AREAS AS BASIS FOR FUTURE GROWTH

              1       Iron Deficiency

                                        ▪ Establish leadership position
                  2      Nephrology     ▪ Fast growing market
                                        ▪ Leverage unique partnership

              3
                      Cardio-Renal

AUGUST 2021                                                               8
NEPHROLOGY – PORTFOLIO OVERVIEW
CONTINUING TO ESTABLISH LEADERSHIP POSITION

Nephrology
revenue
                                                                                                                                                                                        Upcoming launches
                            Creation of                                      launch 2015
                             VFMCRP
                              in 2010
                                                                                                                    launch 2018

                                Initial portfolio                                                                                            Portfolio expansion
                                    1                 1                                 3
Nephrology                                                                                                             KorsuvaTM 2 7               KorsuvaTM 2 7 expansion                              Exploring BD&L
                                                                                    4
portfolio                                                                                                                                                                                                opportunities
                                                                                             Avacopan2         6     Rayaldee® 2 5            Vadadustat2 8             ANG-37772 9

                                 2010                                              2015                                                            2020                                                           2025

1) Sales in chronic kidney disease 2) Pipeline products 3) Licensed from F. Hoffmann-La Roche AG 4) Licensed from Pfizer Inc. 5) Licensed from OPKO Health, Inc. 6) Licensed from ChemoCentryx, Inc.
7) Licensed from Cara Therapeutics, Inc. 8) Licensed from Akebia Therapeutics, Inc., subject to certain conditions and limited to selling vadadustat to certain providers within the US dialysis market 9) Licensed from Angion Biomedica Corp.

AUGUST 2021                                                                                                                                                                                                                                       9
NEPHROLOGY OPPORTUNITIES
LARGE AND GROWING MARKET WITH HIGH UNMET MEDICAL NEED

          COMMERCIAL                 PIPELINE                 BD&L OPPORTUNITIES

                                  Uremic pruritus
                                                             CKD progression drivers
         Iron deficiency     ANCA associated vasculitis
                                                           CKD associated complications
              Anaemia      Secondary hyperparathyroidism
 Diabetic kidney disease                                   Dialysis related complications
                             Cardiac surgery associated
    Hyperphosphatemia         acute kidney injury (AKI)
                                                                Acute kidney injury
          Hyperkalemia       Transplant-associated AKI

                                       C3G                        Transplantation

AUGUST 2021                                                                                 10
NEPHROLOGY – PARTNERSHIP WITH FMC1
UNIQUE EXPERTISE AND PATIENT ACCESS

                STRONG IRON AND PHARMA EXPERTISE                     55%
                                                                    Stake
    ▪ Clinical development
    ▪ Manufacturing, regulatory and market access experiences
    ▪ Global commercial presence
                                                                            Global leadership in nephrology through:
                                                                            ▪ Combination of strengths
                                                                            ▪ Optimal sourcing of innovation
                                                                            ▪ Access to patient data & faster clinical trial execution
                            GLOBAL LEADER IN DIALYSIS                       ▪ Improving outcomes via treatment algorithms

          ~350’000                 >52 million            >4’000
             patients          dialysis treatments p.a.   clinics

                                                                     45%
                                                                    Stake

1) Fresenius Medical Care

AUGUST 2021                                                                                                                              11
VIFOR PHARMA STRATEGIC FOCUS
THREE AREAS AS BASIS FOR FUTURE GROWTH

              1       Iron Deficiency

                  2      Nephrology

                                        ▪ Natural portfolio extension
              3
                      Cardio-Renal      ▪ Strong momentum in Europe
                                        ▪ Significant opportunity with Veltassa®

AUGUST 2021                                                                        12
CARDIO-RENAL – PATIENT POPULATION
NATURAL EXTENSION OF OUR THERAPY AREA FOCUS

                                              CARDIO-RENAL PATIENTS

                                       Reduced kidney                Reduced heart
                                               function              function
                                       associated with               associated with
                                      increased risk of              increased risk of
                                      heart impairment               renal impairment

                                                                                                              HEART FAILURE
                                                      Stage IV     Stage III             Stage II   Stage I
  NEPHROLOGY
               Stage I   Stage II      Stage III      Stage IV   Stage V

                                    NEPHROLOGISTS AND CARDIOLOGISTS
                                        ALREADY TARGETED TODAY

AUGUST 2021                                                                                                                   13
CARDIO-RENAL – FERINJECT® EUROPE
AFFIRM-AHF STUDY SHOWED STRONG CLINICAL BENEFITS
TOTAL HEART FAILURE HOSPITALISATION
                                           100
                                                     Rate ratio (95% CI): 0.74 (0.58–0.94); p=0.013
 Mean cumulative events per 100 patients

                                                                                                                        ▪ 26% reduction in heart failure
                                            80
                                                                                                                          re-hospitalization

                                            60
                                                                                                                        ▪ Reduction irrespective of anemia status
                                                                                                                        ▪ Strengthening of ESC guideline expected
                                            40                                                                            in 2021
                                                                                                                        ▪ Market opportunity over CHF 500m in
                                            20
                                                                                                                          Europe

                                             0
                                                 0      4   8   12     16 20 24 28 32 36 40              44   48   52
                                                                      Time since randomization (weeks)

                                           Ferinject®       Placebo

AUGUST 2021                                                                                                                                                         14
CARDIO-RENAL – INJECTAFER® US
MAJOR UNADDRESSED GROWTH OPPORTUNITY
HFrEF1 PATIENT DROP-OFF – US
                                        410K
                                                                                                                    ▪ Injectafer® label extension based on
                                                                                                                      FAIR-HF & CONFIRM-HF in 2021/22

                                                                                                                    ▪ Further label and guideline
                                                                      21K                    17K                      strengthening following HEART-FID
                                                                                                                      study
           948K

                                                                                                                    ▪ US market opportunity over USD 1
                                                                                                        500K          billion

With iron deficiency                  Other iron             Other i.v. iron             Ferinject®   Not treated
   anaemia (IDA)

1) Heart failure with preserved injection fraction
Source: interviews with US HF specialists, ZS analysis on claims, ATU research, scientific papers

AUGUST 2021                                                                                                                                               15
CARDIO-RENAL – VELTASSA®
SIGNIFICANT OPPORTUNITY WITH EXISTING PRESCRIBERS
IN-MARKET SALES – WORLDWIDE
                                                                                                                               KEY CHARACTERISTICS
        2016                                                            2021                                                   ▪ Calcium-based, non-absorbed
                                                                                                                               ▪ 52-weeks data available
                                                                                                                               ▪ Acute & chronic usage
              1%
                                                       35%
                                                                                                38%
                                                                                                                                KEY FOCUS
          171                                                            441
         CHFm                                                           CHFm                                                    ▪ Establish as therapy of choice for
                                                                                                                                  chronic use
            99%                                                                                                                 ▪ Grow through clinical differentiation
                                                                                                                                  (DIAMOND, CARE-HK, PLATINUM)
                                                                         27%
                                                                                                                                ▪ Maintain and grow coverage

  Veltassa®        Sodium zirconium cyclosilicate          Other potassium binders

Source: monthly IQVIATM MIDAS® panel, GERS, InsightHealth, DLI, moving annual total Q1-2021. Average 2020 exchange rates have been applied.

AUGUST 2021                                                                                                                                                               16
PROVEN BD&L CAPABILITIES & STRONG PIPELINE
KEY UPCOMING LAUNCHES AND DATA READOUTS
      PRE-CLINICAL                             PHASE 1                              PHASE 2                              PHASE 3                             PIPELINE                     LIFE CYCLE MANAGEMENT

       NephThera                                                                                                                                                                                               HEART-FID6
     (Kidney fibrosis)                                                              VIT-2763
                                                                            (Ferroportin inhibitor)                                                                                                              DIAMOND

                                                                                 ANG-37771                                                                                                                       CARE-HK
                                                                                   (CSA-AKI)                                                                                                                    PLATINUM
                                                                                                                      ANG-37771
                                                                                                                         (TA-AKI)
                                                                                                                                                          Rayaldee® 2

                                                                                                                                                          KorsuvaTM 3

                                                                                                                                                           Avacopan4

                                                                                                                                                          Vadadustat5

BD&L = Business development and licensing                      TA-AKI = Transplant-associated acute kidney injury         CSA-AKI = Cardiac surgery associated acute kidney injury
1) Licensed from Angion Biomedica Corp. 2) Licensed from OPKO Health, Inc. 3) Licensed from Cara Therapeutics, Inc. 4) Licensed from ChemoCentryx, Inc. 5) Licensed from Akebia Therapeutics, Inc., subject to certain conditions and
limited to selling vadadustat to certain providers within the US dialysis market 6) Study conducted by our US partner Daiichi Sankyo

AUGUST 2021                                                                                                                                                                                                                             17
AVACOPAN
NEW STANDARD OF CARE IN ANCA-AV

                       Sustain remission                                                                           Reduce glucocorticoid toxicity
         statistically superior at 52 weeks                                                                                       vs. standard of care

                                                                               Avacopan1
      Orphan and rare renal disease                                                                                                   Global rights
         around 50k patients in Europe                                                                                                   excl. US

         Approval in Europe and Japan                                                                                Potential in further indication
                                       2021                                                                                      including C3G and HS

ANCA-AV = Anti-neutrophil cytoplasmic antibody-associated vasculitis   C3G = C3 glomerulopathy   HS = Hidradenitis suppurativa
1) Licensed from ChemoCentryx, Inc.

AUGUST 2021                                                                                                                                              18
KORSUVATM (CR845/DIFELIKEFALIN) INJECTION
INNOVATION IN CKD-ASSOCIATED PRURITUS

   Standard of care with poor efficacy                          ~40% of ESRD patients
         and/or unfavorable safety profile                    moderate to severe CKD-aP

                                             KorsuvaTM 1
               No approved treatment                                   Global rights
                  in the US and Europe                         excl. Japan and South Korea

       Launch in the US in end of 2021                     Leverage commercial organisation
               followed by Europe in 2022                    established presence in dialysis

1) Licensed from Cara Therapeutics, Inc.

AUGUST 2021                                                                                     19
ANG-3777
EXPANDING LEADERSHIP ON THE NEPHROLOGY CHAIN

                     First small molecule                                                                            Global rights2
        hepatocyte growth factor mimetic                                                                         in TA-AKI and CSA-AKI

                                                                                               ANG-37771
        ~110k patients with CSA-AKI                                                                             ~26k patients with TA-AKI
            US, UK and EU4 combined                                                                             US, UK and EU4 combined

              Phase-II study in CSA-AKI                                                                         Phase-III study in TA-AKI
                       read out in H2 2021                                                                       read out in end of 2021

TA-AKI = Transplant-associated acute kidney injury   CSA-AKI = Cardiac surgery associated acute kidney injury
1) Licensed from Angion Biomedica Corp.              2) Excluding China, Taiwan, Hong Kong and Macau

AUGUST 2021                                                                                                                                 20
VIT-2763 (FERROPORTIN INHIBITOR)
TARGETING RARE BLOOD DISORDERS

                                                        Blocks iron transport to              Mechanism similar to
                 Oral small molecule
                                                        the blood                             hepcidin

                                 BETA THALASSEMIA                                  SICKLE CELL DISEASE

Unmet need                       Transfusion burden and iron overload              Pain crisis and and organ damage

Addressable
                                 Approx. 25’000                                    Approx. 150’000
patients1

Phase-II status                  Recruitment completion expected in H2 2021        Study initiated in H1 2021

1) US and EU combined estimate

AUGUST 2021                                                                                                           21
H1 2021 PERFORMANCE
STRONG GROWTH OF THE IRON FRANCHISE
                            Net sales growth at constant exchange rates

Ferinject®/Injectafer®                                                       22.8%

Maltofer®                                                            17.2%

Velphoro®                                                         13.6%

Venofer®                                             2.7%

Veltassa®                               -3.1%

Mircera®/Retacrit®              -9.7%

Net sales                                              5.0%

                         -20%     -10%          0%          10%       20%        30%

AUGUST 2021                                                                            22
P&L OVERVIEW (IN CHF MILLION)
GROSS PROFIT MARGIN UP 1.4 PERCENTAGE POINTS

                                 H1        H1       %∆ vs.
                                                              ▪ Planned decrease in other income due
                                2020 1    2021      H1 2020     to lower partnering activities in H1 2021
Net sales                         846.2     859.3     +1.5%   ▪ Gross profit increase driven by growth of
Other income                       42.2      20.4    -51.7%     high margin iron products
Cost of sales                    -345.9    -329.7     +4.7%
Gross profit                      542.5     550.0     +1.4%   ▪ Strong research and development
Marketing and distribution       -192.3    -193.5     -0.6%     decrease due to CCX140 impairment in
Research and development         -146.6    -108.1    +26.3%     H1 2020, partially offset by investments
General and administration        -90.1     -71.0    +21.2%     in Veltassa® and vamifeport (VIT-2763)
EBIT                              113.5     177.4    +56.3%     studies in H1 2021
Depreciation and amortization    -166.9    -103.7   +37.9%    ▪ General and administration decrease
EBITDA                            280.4     281.0    +0.2%      driven by reduction in personnel related
                                                                costs
                                                              ▪ EBITDA increase by 5.3% at CER or
                                                                15.0% at CER excluding other income
CER = constant exchange rates
1) Restated

AUGUST 2021                                                                                                 23
BALANCE SHEET OVERVIEW (IN CHF MILLION)
STRONG EQUITY RATIO OF 76.5%

                                                 31 Dec     30 Jun       ∆ vs.
                                                  2020       2021      Dec 2020    ▪ Cash & cash equivalents decrease
 Cash & cash equivalents                            730.0      626.2    (104.0)
                                                                                     mainly driven by dividend
 Trade & other receivables                          487.7      509.4       21.7
 Inventories                                        339.8      397.4       57.6
                                                                                     distributions
 Financial investments                              748.8      408.3    (340.5)    ▪ Increase in inventory driven by
 Other assets                                       148.0      231.4       83.4      Veltassa® and Mircera®
 PPE1 & RoU2 assets                                 302.8      296.2       (6.6)
 Intangible assets                                2’454.5    2’447.5       (7.0)
                                                                                   ▪ Financial investments decline
Assets                                            5’211.7    4’916.3    (295.4)      mainly due to the devaluation of
                                                                                     our ChemoCentryx equity stake
 Current financial & lease liabilities               23.0      21.8        (1.2)
                                                                                   ▪ Increase in other assets relates to
 Other current liabilities                          521.0     509.0       (12.0)
 Non-current financial & lease liabilities          608.6     594.1       (14.4)     higher net pension assets and
 Other non-current liabilities                       41.5      28.3       (13.1)     lower deferred tax liabilities
 Shareholders' equity                             4’017.6   3’763.0      (254.6)
Liabilities & shareholders' equity                5’211.7   4’916.3      (295.4)

1) Property, plant & equipment 2) Right-of-use

AUGUST 2021                                                                                                                24
CASH FLOW OVERVIEW (IN CHF MILLION)
NET CASH POSITION OF CHF 86.6 MILLION
                                                                                                               2021
Opening cash & cash equivalents, 1 January                                                                       730.0
    Operating activities                                                                                        288.7        ▪ Change in net working capital mainly due to
    Net working capital                                                                                         (73.4)
                                                                                                                               planned increase in inventory
    Tax payments                                                                                                (25.5)
   Cash flow from operating activities                                                                          189.8        ▪ Capex investments related to production
    Milestones & BD&L1 investments                                                                              (27.5)         facilities in Switzerland as well as software
    Capex & others                                                                                              (40.7)         and IT projects
    Financial investments                                                                                       (30.3)
                                                                                                                             ▪ Financial investments driven by the Angion
   Cash flow from investing activities                                                                          (98.6)
                                                                                                                               Biomedica equity stake of CHF 22.3 million
    Dividends paid                                                                                            (189.8)
    Financing & others                                                                                         (19.1)        ▪ Dividend payments of CHF 129.8 million to
   Cash flow from financing activities                                                                        (208.9)          Vifor Pharma shareholders and CHF 60.0
   Exchange rate effects                                                                                              13.9     million to Fresenius Medical Care
Ending cash & cash equivalents, 30 June                                                                          626.2
    Financial liabilities 2                                                                                   (539.6)
   Net cash                                                                                                      86.6
1) Business development and licensing 2) Excluding non-interest bearing financial liabilities and lease liabilities

AUGUST 2021                                                                                                                                                                    25
GUIDANCE 20211

                            In 2021, at constant exchange rates, net sales are expected
                            to grow at a low-to-mid single digit rate, and EBITDA to grow
                            at a high single digit rate.

1) Subject to no worsening of the situation due to COVID-19 in H2 2021

AUGUST 2021                                                                                 26
OUTLOOK 2021

                                              ▪ Ferinject® approval expected in China
                                              ▪ KorsuvaTM 1 approval expected in the US and filing in Europe
  MARKET ACCESS                               ▪ Avacopan2 approval expected in Europe and Japan
                                              ▪ Avacopan2 & KorsuvaTM 1 partnering in China
                                              ▪ Vadadustat3 filing in the US by our partner Akebia Therapeutics

                                              ▪ Vamifeport phase-II initiation in sickle cell disease in H1 2021
                                              ▪ Vamifeport phase-II recruitment completion in beta thalassemia in H2 2021
  CLINICAL TRIALS
                                              ▪ ANG-37774 phase-II readout in CSA-AKI in H2 2021
                                              ▪ ANG-37774 phase-III readout in TA-AKI in Q4 2021

  BD&L                                        ▪ At least two in-licensing deals, product acquisitions or corporate transactions

CSA-AKI = cardiac surgery-associated acute kidney injury TA-AKI = transplant-associated AKI BD&L = business development and licensing 1) Licensed from Cara Therapeutics, Inc. 2) Licensed from ChemoCentryx, Inc. 3) Licensed from
Akebia Therapeutics, Inc., subject to certain conditions and limited to selling vadadustat to certain providers within the US dialysis market 4) Licensed from Angion Biomedica Corp.

AUGUST 2021                                                                                                                                                                                                                      27
CONTACT INFORMATION

                                                                    Investor relations

  Colin Bond                          Julien Vignot                           Laurent de Weck
  Chief Financial Officer             Head of Investor Relations              Investor Relations Senior Manager
  Phone: +41 58 851 83 53             Phone: +41 58 851 66 90                 Phone: +41 58 851 80 95
  Email: colin.bond@viforpharma.com   Email: julien.vignot@viforpharma.com    Email: laurent.deweck@viforpharma.com

AUGUST 2021                                                                                                           28
DISCLAIMER

Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company’s or, as
appropriate, the Company’s directors’ current expectations and projections about future events. By their nature, forward-
looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to
differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A
multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events,
performance or results to differ significantly from any anticipated development. Forward-looking statements contained
in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities
will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any
change in events, conditions, assumptions or circumstances on which these forward-looking statements are based.
Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any
such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in
this presentation or the actual occurrence of the forecasted developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this presentation.

AUGUST 2021                                                                                                                  29
You can also read